Protecting the Future of Medical Innovation For Patient Needs

By Carine Boustany, Ph.D., SVP, US Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim

At Boehringer Ingelheim, we innovate ground-breaking medicines to address unmet medical needs with the purpose of helping patients’ overall lives and wellbeing today, tomorrow and for generations to come.

But a real threat is looming in Washington, and our innovation and all the innovation happening across the life science industry is in danger. The proposed legislation H.R. 3 risks government control of the availability of medicines, which would impede investment potential for the development of new medicines, treatments and potential cures for pervasive illnesses.